yuelan
Johnson & Johnson (JNJ) is evaluating an offer to purchase Intra-Cellular Therapies (NASDAQ:ITCI).
Deliberations are on going, and it’s not a certainty that JNJ will make an offer for the biotech firm focused on treatments for mental health disorders, according to a